Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue
(feeds.content.dowjones.io)
1.
2.
3.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion
(feeds.content.dowjones.io)
4.
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets
(feeds.content.dowjones.io)
5.
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion
(feeds.content.dowjones.io)